Pharmaceutical compositions comprising GLP-1 peptides or exendin-4 and a basal insulin peptide

Abstract

Pharmaceutical composition for parenteral administration comprising a basal insulin peptide and an insulinotropic GLP-1 peptide comprising at least 6 zinc atoms per 6 insulin molecules.

Description

field of invention [0001] The present invention relates to the field of pharmaceutical compositions. More specifically, the present invention relates to pharmaceutical compositions containing two different pharmaceutically active peptides. Background technique [0002] Diabetes mellitus is a metabolic disease in which the ability to utilize glucose is partially or completely lost. Since the introduction of insulin in the 1920s, there have been continuous efforts to improve the treatment of diabetes. With decades of chronic treatment for diabetic patients, there is a great need for insulin formulations that are safe, convenient and improve quality of life. [0003] In the treatment of diabetes, many different insulin formulations have been proposed and used, such as regular insulin, protamine zinc insulin (expressed as NPH), insulin zinc suspension (such as Semilente 、Lente and Ultralente ) and biphasic protamine zinc insulin. Some commercially available insulin form...

AI Technical Summary

Problems solved by technology

Some commercially available insulin formulations are characterized by a rapid onset of action, while others have a relatively slow onset of action but show a more or less prolonged efficacy

Images